All Stories

  1. Male Sex, B Symptoms, Bone Marrow Involvement, and Genetic Alterations as Predictive Factors in Diffuse Large B-Cell Lymphoma

    Article • International Journal of Molecular Sciences, May 2025, MDPI AG

    Barbara Jezeršek Novaković

  2. Are there clinically relevant prognostic factors in diffuse large B-cell lymphoma beyond International Prognostic Index?

    Article • Radiology and Oncology, April 2025, De Gruyter

    Barbara Jezeršek Novaković

  3. The Impact of Bone Marrow Involvement on Prognosis in Diffuse Large B-Cell Lymphoma: An 18F-FDG PET/CT Volumetric Segmentation Study

    Article • Cancers, November 2024, MDPI AG

    Barbara Jezeršek Novaković

  4. Detection performance and prognostic value of initial bone marrow involvement in diffuse large B-cell lymphoma: a single centre 18F-FDG PET/CT and bone marrow biopsy evaluation study

    Article • Radiology and Oncology, February 2024, De Gruyter

    Barbara Jezeršek Novaković

  5. Do Double-Expressor High-Grade B-Cell Lymphomas Really Need Intensified Treatment? A Report from the Real-Life Series of High-Grade B-Cell Lymphomas Treated with Different Therapeutic Protocols at the Institute of Oncology Ljubljana

    Article • Biomedicines, January 2024, MDPI AG

    Barbara Jezeršek Novaković

  6. Correlation of t(14;18) translocation breakpoint site with clinical characteristics in follicular lymphoma

    Article • Radiology and Oncology, July 2023, De Gruyter

    Barbara Jezeršek Novaković

  7. CD56-positive diffuse large B-cell lymphoma: comprehensive analysis of clinical, pathological, and molecular characteristics with literature review

    Article • Radiology and Oncology, March 2023, De Gruyter

    Barbara Jezeršek Novaković

  8. Molecular Mechanisms of Gastrointestinal Stromal Tumors and Their Impact on Systemic Therapy Decision

    Article • Cancers, February 2023, MDPI AG

    Barbara Jezeršek Novaković

  9. Correlation of treatment outcome in sanger/RT‑qPCR KIT/PDGFRA wild‑type metastatic gastrointestinal stromal tumors with next‑generation sequencing results: A single‑center report

    Article • Oncology Reports, July 2022, Spandidos Publications

    Barbara Jezeršek Novaković

  10. Trends in specialized palliative care referrals at an oncology center from 2007 to 2019

    Article • BMC Palliative Care, September 2021, Springer Science + Business Media

    Barbara Jezeršek Novaković

  11. Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma

    Article • Therapeutics and Clinical Risk Management, March 2021, Taylor & Francis

    Barbara Jezeršek Novaković

  12. Diffuse large B-cell lymphoma: 10�years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone

    Article • Oncology Letters, January 2018, Spandidos Publications

    Barbara Jezeršek Novaković

  13. THE PROGNOSTIC VALUE OF FLIPI IN THE ERA OF RITUXIMAB

    Article • Hematological Oncology, June 2017, Wiley

    Barbara Jezeršek Novaković

  14. Pharmacokinetics of monoclonal antibody rituximab.

    Article • British Journal of Clinical Pharmacology, March 2017, Wiley

    Iztok Grabnar, Barbara Jezeršek Novaković

  15. Changes in expression of genes involved in antitumor immunity in mice vaccinated with tumor vaccine composed of irradiated syngeneic tumor cells and CpG oligodeoxynucleotides

    Article • Molecular Immunology, November 2016, Elsevier

    Barbara Jezeršek Novaković

  16. The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients

    Article • Oncology Letters, April 2016, Spandidos Publications

    Barbara Jezeršek Novaković

  17. Outcome of severe infections in afebrile neutropenic cancer patients

    Article • Radiology and Oncology, February 2016, De Gruyter

    Barbara Jezeršek Novaković

  18. Stem cell transplantation in follicular and mantle cell lymphomas

    Article • Radiology and Oncology, January 2016, De Gruyter

    Barbara Jezeršek Novaković

  19. Granulomatosis after autologous stem cell transplantation in nonHodgkin lymphoma – experience of single institution and a review of literature

    Article • Radiology and Oncology, January 2016, De Gruyter

    Barbara Jezeršek Novaković

  20. Fertility in young patients following treatment for Hodgkin’s lymphoma: a single center survey

    Article • Journal of Assisted Reproduction and Genetics, December 2015, Springer Science + Business Media

    Barbara Jezeršek Novaković

  21. Checkpoint inhibitors in Hodgkin's lymphoma

    Article • European Journal Of Haematology, December 2015, Wiley

    Barbara Jezeršek Novaković

  22. Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors

    Article • Radiology and Oncology, November 2015, De Gruyter

    Barbara Jezeršek Novaković

  23. Immunotoxin – a new treatment option in patients with relapsed and refractory Hodgkin lymphoma

    Article • Radiology and Oncology, November 2015, De Gruyter

    Barbara Jezeršek Novaković

  24. Outcomes of Treatment in Slovene Follicular Lymphoma Patients

    Article • Clinical Lymphoma Myeloma & Leukemia, October 2015, Elsevier

    Barbara Jezeršek Novaković

  25. 3234 The impact of translocation t(14;18) on the outcome of follicular lymphoma patients

    Article • European Journal of Cancer, September 2015, Elsevier

    Barbara Jezeršek Novaković

  26. Diagnostic value of immunoglobulin κ light chain gene rearrangement analysis in B-cell lymphomas

    Article • International Journal of Oncology, December 2014, Spandidos Publications

    Barbara Jezeršek Novaković

  27. Clonality analysis of lymphoid proliferations using the BIOMED-2 clonality assays: a single institution experience

    Article • Radiology and Oncology, April 2014, De Gruyter

    Barbara Jezeršek Novaković

  28. Ofatumumab Can Induce Remission in Refractory Burkitt's Lymphoma – A Case Report

    Article • Blood, November 2012, American Society of Hematology

    Barbara Jezeršek Novaković

  29. Treatment outcomes and survival in patients with primary central nervous system lymphomas treated between 1995 and 2010 – a single centre report

    Article • Radiology and Oncology, October 2012, De Gruyter

    Barbara Jezeršek Novaković

  30. Late-onset neutropenia following primary treatment of diff use large B-cell lymphoma with rituximab-containing therapy

    Article • Leukemia & Lymphoma, May 2012, Taylor & Francis

    Barbara Jezeršek Novaković

  31. Eleven years of experience with AIDS-related lymphomas at the Institute of Oncology Ljubljana

    Article • Medical Oncology, April 2011, Springer Science + Business Media

    Barbara Jezeršek Novaković

  32. The predictive significance of CD20 expression in B-cell lymphomas

    Article • Diagnostic Pathology, April 2011, Springer Science + Business Media

    Barbara Jezeršek Novaković

  33. Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity

    Article • BMC Immunology, September 2010, Springer Science + Business Media

    Barbara Jezeršek Novaković

  34. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma

    Article • Oncology Reports, September 2010, Spandidos Publications

    Barbara Jezeršek Novaković

  35. Class C CpG oligodeoxynucleotides as a single agent and in combination with radiotherapy efficiently delayed growth of subcutaneous B16F1 tumors

    Article • Innate Immunity, September 2009, SAGE Publications

    Barbara Jezeršek Novaković

  36. Treatment of NonHodgkin’s lymphomas with rituximab in Slovene patients

    Article • Medical Oncology, March 2009, Springer Science + Business Media

    Barbara Jezeršek Novaković

  37. Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs

    Article • Vaccine, November 2007, Elsevier

    Barbara Jezeršek Novaković

  38. A single-center study of treatment outcomes and survival in patients with primary gastric lymphomas between 1990 and 2003

    Article • Annals of Hematology, August 2006, Springer Science + Business Media

    Barbara Jezeršek Novaković

  39. Dendritic cells incubated with irradiated tumor cells effectively stimulate T lymphocyte activation and induce enhanced expression of CD69, CD25 as well as production of IFNγ and IL4

    Article • International Immunopharmacology, January 2006, Elsevier

    Barbara Jezeršek Novaković

  40. The circulating auto-antibodies to p53 protein in the follow-up of lymphoma patients.

    Article • Oncology Reports, January 2001, Spandidos Publications

    Barbara Jezeršek Novaković

  41. NEW TNF-α ANALOGUES: A POWERFUL BUT LESS TOXIC BIOLOGICAL TOOL AGAINST TUMOURS

    Article • Cytokine, August 1997, Elsevier

    Barbara Jezeršek Novaković

  42. Clinical evaluation of potential usefulness of CEA, CA 15-3, and MCA in follow-up of breast cancer patients

    Article • Cancer Letters, December 1996, Elsevier

    Barbara Jezeršek Novaković

  43. Interactions of interferon and vinblastine on experimental tumor modei melanoma B-16 in vitro

    Article • Anti-Cancer Drugs, February 1994, Wolters Kluwer Health

    Barbara Jezeršek Novaković